Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic and Blood Pressure (BP) Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4G 3E8
- Local Institution
-
-
Quebec
-
Laval, Quebec, Canada, H7T 2P5
- Local Institution
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- Local Institution
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Res Inst
-
Lomita, California, United States, 90717
- Torrance Clinical Research
-
-
Florida
-
Miami, Florida, United States, 33169
- Elite Research Institute
-
Orlando, Florida, United States, 32806
- Compass Research, LLC
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- University of Michigan
-
-
Minnesota
-
St. Paul, Minnesota, United States, 55114
- Prism Research
-
-
Rhode Island
-
Pawtucket, Rhode Island, United States, 02860
- Memorial Hospital of Rhode Island
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53295
- Zablocki Veterans Affairs Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 6.6 and ≤ 9.5%
- Stable dose of metformin AND/OR a sulfonylurea, for at least 4 weeks prior to the enrollment visit
- Inadequate blood pressure (BP) control, defined as systolic BP (SBP) ≥ 130 and < 165 mmHg, AND/OR diastolic BP (DBP) ≥ 80 and < 105 mmHg
- C-peptide ≥ 0.8 ng/mL
- Estimated GFR by the Modification of Diet in Renal Disease (MDRD) formula > 60 mL/min/1.73m² and < 150 mL/min/1.73m²
- Urine albumin:creatinine ratio (UACR) < 300 mg/g
- BMI ≤ 45.0 kg/m2
Exclusion Criteria:
- Administration of diuretics or other medication approved for the treatment of hypertension (with the exception of either ACEI or ARB), at any dose during the 12 weeks prior to the enrollment visit
- History of adverse reaction to radio-contrast dye
- Allergy or contraindication to use of thiazide diuretics
- Aspartate Aminotransferase (AST) > 3X Upper limit of normal (ULN)
- Alanine aminotransferase (ALT) > 3X ULN
- Serum Total Bilirubin > 1.5X ULN
- Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women
- Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncologic, endocrine, psychiatric, or rheumatic diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dapagliflozin
|
Tablets, Oral, 0 mg, once daily, 12 weeks
Tablets, Oral, 10 mg, once daily, 12 weeks
Other Names:
|
|
Active Comparator: Hydrochlorothiazide
|
Tablets, Oral, 25 mg, once daily, 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjusted Percent Change From Baseline in Glomerular Filtration Rate (GFR) at Week 12 (Modified Last Observation Carried Forward [MLOCF])
Time Frame: From Baseline to Week 12
|
Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication.
In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
If no Week 12 measurement was available, the last available post-baseline measurement obtained on or after Day 23 was used regardless of rescue medication.
Measurements were obtained during radomization visit, and Week 12 in the double-blind period by a central laboratory.
|
From Baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjusted Mean Change From Baseline in 24-Hour Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])
Time Frame: From Baseline to Week 12
|
Data after rescue medication was excluded from this analysis.
Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication.
In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Measurements were obtained during lead-in, and Week 12 in the double-blind period.
|
From Baseline to Week 12
|
|
Adjusted Mean Change From Baseline in Daytime (0900 to 2100 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])
Time Frame: From Baseline to Week 12
|
Data after rescue medication was excluded from this analysis.
Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication.
In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Measurements were obtained during lead-in, and Week 12 in the double-blind period.
|
From Baseline to Week 12
|
|
Adjusted Mean Change From Baseline in Nighttime (0100 to 0600 Hours) Ambulatory Systolic Blood Pressure (ASBP) at Week 12 (Last Observation Carried Forward [LOCF])
Time Frame: From Baseline to Week 12
|
Data after rescue medication was excluded from this analysis.
Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication.
In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Measurements were obtained during lead-in, and Week 12 in the double-blind period.
|
From Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium Chloride Symporter Inhibitors
- Dapagliflozin
- Hydrochlorothiazide
Other Study ID Numbers
Other Study ID Numbers
- MB102-035
- EUDRACT #: 2009-010221-39
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.